Trials / Terminated
TerminatedNCT02368691
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- GTx · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTx-024 | GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-09-22
- Completion
- 2017-09-22
- First posted
- 2015-02-23
- Last updated
- 2020-11-18
- Results posted
- 2020-10-30
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02368691. Inclusion in this directory is not an endorsement.